“I Believe That Pharmaceutical Companies Can Do More than Providing Medicines” (Page)
https://www.swisstph.ch/en/impact-stories/i-believe-that-pharmaceutical-companies-can-do-more-than-providing-medicines
and bring medicines to market in low- and middle-income countries. We work on diseases such as malaria, leishmaniasis and dengue fever, which primarily affect poorer countries and marginalised communities [...] development of new medicines. We can’t tackle tomorrow’s challenges with the tools of yesterday. In malaria, where there hasn’t been a new medicine in 25 years, drug resistance is on the rise. Novartis, together [...] these communities. The success we have achieved as a global community...
Statistical and Mathematical Modelling | Swiss TPH (Page)
https://www.swisstph.ch/en/statistical-and-mathematical-modelling
disease patterns, and in mathematical and simulation modelling of infectious diseases, particularly malaria, tuberculosis and other poverty-related diseases. At Swiss TPH, we analyse a wide range of disease
Host cytoskeleton remodeling throughout the blood stages of <em>Plasmodium falciparum</em> (Publications)
asexual intraerythrocytic development of Plasmodium falciparum, causing the most severe form of human malaria, is marked by extensive host cell remodeling. Throughout the processes of invasion, intracellular
Predictors of residual antimalarial drugs in the blood in community surveys in Tanzania (Publications)
cross-sectional survey was conducted in 2015 in three regions of Tanzania with different levels of malaria endemicity. Interviews were conducted and blood samples collected through household surveys for further
Antiprotozoal activities of some constituents of <em>Markhamia tomentosa</em> (Bignoniaceae) (Publications)
bloodstream trypomastigotes of Trypanosoma brucei rhodesiense (the species responsible for human malaria, visceral leishmaniasis and African trypanosomiasis, respectively). Although compounds 1 and 2 exhibited
Solid phase synthesis and antiprotozoal evaluation of di- and trisubstituted 5'-carboxamidoadenosine analogues (Publications)
rapid increase of resistance to drugs commonly used in the treatment of tropical diseases such as malaria and African sleeping sickness calls for the prompt development of new safe and efficacious drugs
Antiplasmodial and antitrypanosomal activity of new esters and ethers of 4-dialkylaminobicyclo[2.2.2]octan-2-ols (Publications)
suffer from painful application, severe side effects and increasing resistance against these drugs. Malaria tropica kills more than 2 million people every year mainly due to growing drug resistance. 4-Dia
A <em>Plasmodium falciparum</em> bromodomain protein regulates invasion gene expression (Publications)
expression of invasion genes and indicate that targeting PfBDP1 could be an invaluable tool in malaria eradication
Genesis of and trafficking to the Maurer's clefts of <em>Plasmodium falciparum</em>-infected erythrocytes (Publications)
Malaria parasites export proteins beyond their own plasma membrane to locations in the red blood cells in which they reside. Maurer's clefts are parasite-derived structures within the host cell cytoplasm
Estimation of infection and recovery rates for highly polymorphic parasites when detectability is imperfect, using hidden Markov models (Publications)
implemented using Markov chain Monte Carlo simulation. The model is applied to a panel data set of malaria genotype data from a randomized controlled trial of bed nets in Tanzanian children aged 6-30 months